Please login to the form below

Not currently logged in
Email:
Password:

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

Leverkusen, Germany-based Bayer has promoted Robert LaCaze to executive vice president of its new oncology strategic business unit, part of the firm's pharmaceutical division.

LaCaze joins the pharmaceutical division's executive committee, and will be responsible for implementing the new unit's accelerated development model for new oncology therapies.

He first joined Bayer in 2015 and most recently served as senior vice president and head of global oncology therapeutic area at the firm.

Prior to this, LaCaze spent 27 years at Bristol-Myers Squibb, holding a series of increasingly senior oncology-focused managerial roles, before becoming senior vice president and head of product and portfolio strategy at Bristol-Myers Squibb in 2014.

Dieter Weinand, head of the Bayer Pharmaceutical executive committee, said: “We are delighted to have an executive with Robert LaCaze's experience and talent lead the Oncology Strategic Business Unit.

“I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”

9th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics